Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Tailruibapate tablets have obtained the pharmaceutical registration certificate.

Gelonghui, December 3rd | shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary, Peking Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail" or "subsidiary" below), has received the registration certificate for the Rupatadine tablets issued by the National Medical Products Administration (Certificate No.: 2024S02910). Rupatadine tablets were registered for Class 4 chemical drugs application, and after approval, they are considered to have passed the consistency evaluation of generic drug quality and efficacy. Rupatadine tablets are mainly used to improve gastric ulcers, acute gastritis, and acute exacerbation of chronic gastritis with gastric mucosal lesions, including erosion, bleeding, congestion, and edema.

Gelonghui FinanceDec 3 03:44 ET

shandong jincheng pharmaceutical group (300233.SZ): jincheng tai er chlorhexidine production line successfully passed pharmaceutical GMP compliance inspection

Gelonghui November 25th, shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary, Peking Jincheng Tail Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Tail"), has received the "Drug GMP Compliance Inspection Inform Letter" (Number: Jingya Jin GMP [2024] 020072) approved and issued by the Beijing Drug Administration. Inspection scope and related production workshops, production lines: Chloroquine Phosphate (Registration No: Y20220000707) (In the western area of Langang Economic and Technological Development Zone, Cangzhou City, Hebei Province, north of Erliu Road and east of Weli Road, Workshop 1: Chloroquine Phosphate production.

Gelonghui FinanceNov 25 05:14 ET

Shandong Jincheng Pharmaceutical Group (300233.SZ): Equipped with a composite, multi-technology biosynthesis and chemical synthesis dual platform.

Gelonghui, November 21st | Shandong Jincheng Pharmaceutical Group (300233.SZ) stated in recent investor relations activities that the company has a composite, multi-technical dual platform for biological synthesis and chemical synthesis, with about 2,000 chemical synthesis team members and 400 synthetic biologists. The dual-platform advantage solves the problems of low efficiency and high cost in traditional products and traditional industries. The company's product selection is focused on the pharmaceutical + health industry, with certain technological barriers.

Gelonghui FinanceNov 21 07:12 ET

Shandong Jincheng Pharmaceutical Group's Antibiotic Gets Chinese Drug Regulator's Approval

MT NewswiresNov 6 04:27 ET

shandong jincheng pharmaceutical group (300233.SZ): Cefamandole nafate dry suspension passed consistency evaluation

shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary shanghai jinchengsuzhi pharmaceutical co., ltd. (referred to as ...

Zhitong FinanceNov 5 04:10 ET

Solid Earnings May Not Tell The Whole Story For Shandong Jincheng Pharmaceutical Group (SZSE:300233)

Simply Wall StOct 31 18:59 ET